Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 4, 2002, Pages 1086-1092

  Kantor, Rami ^a   Fessel, W Jeffrey ^a   Zolopa, Andrew R ^a   Israelski, Dennis ^a   Shulman, Nancy ^a   Montoya, Jose G ^a   Harbour, Michael ^a   Schapiro, Jonathan M ^a   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SALVAGE THERAPY; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; RNA, VIRAL; SALVAGE THERAPY;

EID: 0036203533     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.4.1086-1092.2002     Document Type: Article

References (27)

1. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
2. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
3. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
4. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
5. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
6. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
7. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
8. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population
9. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6,000 samples
10. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
11. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
12. HIV signature and sequence variation analysis
13. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
14. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
15. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir
16. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
17. Resistance to protease inhibitors
18. Simple methods for estimating the numbers of synonymous and nonsynonymous nucteotide substitutions
19. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients
20. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
21. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
22. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
23. Virologic responses to a ritonavirsaquinavir-containing regimen in patients who had previously failed nelfinavir
24. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
25. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy
26. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
27. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed